The Outpatient Prospective Payment System (OPPS) proposed rule has come out! It will take time to read and digest so details will follow. At first glance, there are no changes to Cellular Tissue Product /skin substitute payment, which remain under package pricing in this site of care. Of note, “skin substitutes” are considered medical supplies for payment purposes. Stay tuned for more information as the proposed rule is evaluated.
Here is a link to the CMS fact sheet.
Submit the form below to receive email alerts when Intellicure publishes a new blog post! This information will not be shared.
You May Also Like …
LCD – Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (L39756)
It would eliminate the 2.8% Medicare physician payment cut and provide a positive update that equals half of the Medicare Economic Index.
Baxter International is one of the largest suppliers of IV fluids in the United States with its North Cove facility providing 60% of IV fluid in the USA.